An observational study in Metastatic Breast Cancer, sponsored by UNICANCER. Recruiting at 20 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by UNICANCER · Observational
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Breast Neoplasms by UNICANCER — 15 open to participants now, 27 under way, 7 of them phase 3. Breast Neoplasms · UNICANCER.
Among the 64 studies in Breast Neoplasms by UNICANCER, this one is one of 2 that started in 2014, is one of 4 observational ones, reaches primary completion later than 12 of the 26 other live ones, and was the 37th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →15 of the 64 studies in Breast Neoplasms by UNICANCER are open now, in 9 countries. Recruiting first, the newest first:
UNICANCER · Sites in France
Ages 60+ · Women only
UNICANCER · Sites in Belgium, France, Greece and 4 more countries
Ages 35–45 · Women only
UNICANCER · Sites in France, Italy
Ages 40–74 · Women only · Healthy volunteers
UNICANCER · Sites in France, Germany, Italy and 2 more countries
Ages 18+ · Women only
UNICANCER · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 29 · Phase 3 15
First in 1994; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 42,000 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 170 across the 59 interventional studies, 467 across the 4 observational. Of the 36 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
UNICANCER is the lead sponsor of 219 studies on the registry; 52 are open to participants now.
3 of the studies in Breast Neoplasms by UNICANCER that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03246841UNICANCERInvestigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes. | 2026-12-30 |
| NCT07120087UNICANCEREvaluation of an Online Intervention to Educate Women at High Risk of Breast Cancer on How to Help Reduce Their Risk. | 2026-12-31 |
| NCT03275311UNICANCEREvolution of the Therapeutic Care in Metastatic Breast Cancer From 2008 | 2027-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 64 studies in Breast Neoplasms by UNICANCER, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Epidemiological Strategy and Medical Economic (ESME) Breast cancer Database is a multicenter real life database using a retrospective data collection process across 18 French comprehensive cancer centers (FCCC) spread over 20 sites. This database compiles data from patient's electronic medical records (EMR).
This database compiles existing data retrieved fromp patient's electronic medical records (EMR) across the 18 French comprehensive cancer centers spread over 20 sites. .
The database includes data related to patient demographics, tumor characteristics (diagnosis, histology, relapses, metastatic disease, etc.), treatments (dates, INN, route of administration, treatment protocols, reason for termination, etc.), and clinical events. Data is collected at each participating site by technicians who are specifically trained for the project using an electronic data collection (eDC) tool.
Data imported into the final database are controlled, recoded, and harmonized before import according to the data management plan. All coding procedures are predefined by the data manager. There is no transmission of individual data; all data are centralized within each center using a shared anonymous format. All data is exclusively obtained retrospectively; no attempts are made to recover non available data from the patient's medical record by contacting healthcare providers or patients.
Cases selected to enter the ESME MBC data platform fulfill specific criteria: (1) Male or female ≥18 years old (2) metastatic breast cancer (3) with first metastasis treated (either completely or partially) at a participating site from January 2008 onwards.Treatment strategies considered include radiotherapy, chemotherapy, targeted therapy and endocrine therapy.
All consecutive patients treated for a metastatic breast cancer in a French Comprehensive Cancer Center over the selection period.
Inclusion criteria :
Exclusion criteria : None
Describe the evolution of therapeutic care
Patient characteristics, tumor characteristics and treatment patterns
Time frame: baseline
Describe the impact of therapeutic strategies on survival criteria
Overall survival
Time frame: From date of diagnosis or first treatment until the date of date of death from any cause. Follow up until 2023.
Describe the impact of therapeutic strategies on survival criteria
Progression free survival
Time frame: From date of diagnosis or first treatment until the date of first documented progression or date of death from any cause. Follow up until 2023.
Plan to share: No
Started Jul 2014 (actual). Primary completion is estimated for Mar 2027, 152 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.